Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

December deadline nears for applying for position on EU pharmacovigilance PRAC committee

This article was originally published in SRA

Executive Summary

The 1 December deadline is nearing for interested parties to inform the European Commission that they are interested in becoming a member of the Pharmacovigilance Risk Assessment Committee that the European Medicines Agency is required to set up in July 20121,2.

You may also be interested in...



Potential Cardiovascular Blockbuster Inclisiran Among New Filings At EMA

The European Medicines Agency has agreed to review pan-EU marketing applications for a number of new medicines.

Novel Ticagrelor Reversal Agent Wins Place On EMA’s PRIME

Only two of seven recent applications for entry into the European Medicines Agency’s priority medicines scheme for getting treatments for unmet medical needs to patients faster made the grade.

New CLL Treatment Paradigm Nears In EU For AbbVie

The first chemotherapy-free, first-line treatment for chronic lymphocytic leukemia where dosing can be completed in one year has received the thumbs up by the European Medicines Agency.

UsernamePublicRestriction

Register

PS116548

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel